BIIB vs JAKK · P/E 21, rev $9.89B vs P/E 4.9, rev $245.9M
Biogen Inc (BIIB) versus JAKKS Pacific Inc (JAKK) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ. It is led by Christopher A. Viehbacher.
JAKKS Pacific Inc (JAKK) is a leisure company listed on US.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported JAKK revenue for 2026-06-30 was $245.9M. Net income was $1.6M. JAKK currently screens at market cap $231.6M and trailing P/E 4.9.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. JAKK currently screens at market cap $231.6M and trailing P/E 4.9.
Not investment advice. Open the BIIB and JAKK stock pages for the full models.
Not investment advice.